← Back to Clinical Trials
Recruiting NCT06575140

NCT06575140 Associative Peripheral Stimulation for Reduction of Motor Impairment During Acute Period of Stroke Recovery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06575140
Status Recruiting
Phase
Sponsor Ahmed A. Rahim
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2021-12-18
Primary Completion 2024-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 79 Years
Study Type INTERVENTIONAL
Interventions
Associative Peripheral Stimulation (APS) 1.0Peripheral Neuromuscular Stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2021-12-18 with a primary completion date of 2024-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Associative Peripheral Stimulation (APS) is a non-invasive therapy intended for stroke rehabilitation involving transcutaneous electrical muscle stimulation paired with voluntary movement. This pilot study investigates whether APS applied during the acute phase of stroke recovery may reduce impairment and improve function in the affected upper extremity.

Eligibility Criteria

Inclusion Criteria: 1. Confirmed ischemic or hemorrhagic stroke no earlier than 7 days prior to enrollment; 2. Presentation of hemiparesis or paralysis of the upper extremity due to stroke; 3. Ability to comprehend and follow study instructions; 4. Ability to initiate finger extension (≥3°) at least three times per minute; 5. Fugl-Meyer Assessment (Upper Extremity) score of \<47. Exclusion Criteria: 1. Contraindications, intolerance, or high sensitivity to the experimental protocol; 2. History of upper-extremity disability prior to the index stroke; 3. Neurological conditions (other than stroke) affecting motor function; 4. Treatment of spasticity/increased tone in the affected upper extremity (e.g., with Botox injection); 5. Lack of access to a safe and suitable place of discharge for experimental sessions and follow-up visits.

Contact & Investigator

Central Contact

Ahmed A Rahim, MTM

✉ ahmed.rahim@alumni.ucsf.edu

📞 +1 (916) 825-8792

Principal Investigator

Daniel San Juan Orta, MD

STUDY DIRECTOR

National Institute of Neurology & Neurosurgery

Frequently Asked Questions

Who can join the NCT06575140 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 79 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06575140 currently recruiting?

Yes, NCT06575140 is actively recruiting participants. Contact the research team at ahmed.rahim@alumni.ucsf.edu for enrollment information.

Where is the NCT06575140 trial being conducted?

This trial is being conducted at Mexico City, Mexico, Mexico City, Mexico, Mexico City, Mexico.

Who is sponsoring the NCT06575140 clinical trial?

NCT06575140 is sponsored by Ahmed A. Rahim. The principal investigator is Daniel San Juan Orta, MD at National Institute of Neurology & Neurosurgery. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology